StonvexLoading…
StonvexStonvexStonvexAEON Biopharma will present data at the 68th Annual American Headache Society meeting demonstrating that its biosimilar candidate ABP-450 shows structural and functional comparability to BOTOX®, with LC-MS peptide mapping achieving 93%-99% sequence coverage and potency assays meeting equivalence criteria.
AEON Biopharma announced presentation of analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the American Headache Society meeting. The data demonstrates highly similar biological activity through multiple analytical approaches, with LC-MS peptide mapping showing 93%-99% sequence coverage and LD50 potency assay results falling within equivalence criteria established from BOTOX® reference results.
Summary and sentiment are generated by AI for educational purposes. Always verify with the original source before making investment decisions.
Risk warning
Investing in equities carries significant risk, including the potential loss of your entire investment. Volatility, liquidity, geopolitical, and currency risks can all materially affect outcomes. Past performance does not guarantee future results. Nothing on Stonvex is investment advice, a recommendation, or a solicitation to buy or sell any security. Stonvex is not a registered investment advisor (RIA), broker-dealer, or financial planner. You should consult a licensed advisor before making investment decisions and only invest capital you can afford to lose.
© 2026 Stonvex. All rights reserved.
Service not available to residents of: Belarus, China, Cuba, France, Germany, India, Iran, Japan, North Korea, Russia, South Korea, Sudan, Syria. See Terms. You must be 18 years or older to use this service.